All News
In RA after first-line TNFi, improvements in disease activity & PROs were seen with 2nd line ETN and JAKi. Some measures had greater improvement in JAKi group. Some patients can benefit from TNF cycling. Pappas D CorEvitas Abs1588 https://t.co/cHW5tm97kx #ACR22 @RheumNow https://t.co/bx0p04AQzd
Dr. Antoni Chan synovialjoints ( View Tweet)
Abs 1559 at #ACR22 long-term efficacy of apremilast differs between oral and genital ulcers, skin lesions and joint lesions. There may be differences in the long-term efficacy of apremilast dependent on manifestation type. @RheumNow https://t.co/I8p5fd1CA1 https://t.co/XKjpIUeiah
Dr. Rachel Tate uptoTate ( View Tweet)
In this study by Stoots et al, #lupus pts w/ ⬇️ CV risk (accdg to ASCVD risk calc) had significantly abn. CAC vs. controls and assoc with:
🦋Older age, ⬇️GFR, ⬆️TC&LDL, longer dse duration.
More data needed but consider regular CV screens in these pts
#ACR22 @RheumNow ABST#1596 https://t.co/pECZw1n6lb
sheila RHEUMarampa ( View Tweet)
What should you use as a second-line biologic in PsA patients?
In pts who discontinued TNFi, switching to a different MOA led to comparable or better outcomes vs. cycling through another TNFi.
Abs#1600 @RheumNow #ACR22 https://t.co/9MZPSHD7we
Robert B Chao, MD doctorRBC ( View Tweet)
Spangler et al. No increased risk of MI or stroke in denosumab vs zoledronate in 170,000 patients from Optum/MarketScan. @RheumNow #ACR22 Abstr#0575 https://t.co/5fho4WBsIG https://t.co/PNCI4xJ38u
Richard Conway RichardPAConway ( View Tweet)
Does curcumin help maintain drug-free remission RA?
Answer is No
Single center RCT Curcumin vs PBO w/ MTX withdrawal
= flare-free survival
= median time to flare (219 d vs. 214 d)
Serum curcuminoid levels not asso w/ flares
https://t.co/3U6W0Iuqrq
Abs#1587 #ACR22 @Rheumnow https://t.co/GwAsY7OKTX
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Metabolic disorders +diet patterns PsA
👉71.9% obese
👉metabolic synd 46.9%
👉dyslipid 41.9%
👉 HTN 37.5%
Diet patterns assoc Dx activity
⬇️sugar⬇️fatigue⬇️PSAID score
⬆️whole fruit ⬇️SJC
⬆️unsat fats ⬆️enthesitis
DIPSA -Med/DASH diet PsA ongoing
#ACR22 @RheumNow Abst1007 https://t.co/cbggEw6IZp
Patricia Harkins DrTrishHarkins ( View Tweet)
TOFA and MTX: which one to withdraw first?
RCT in 100+ RA pts in remission after 1 yr, 1 yr follow-up
Withdraw MTX grp: Remission 30% LDA 40%
Withdraw TOFA grp: Remission 50% LDA 65%
diff NS small sample
8 SAEs, 72% recovery
https://t.co/tMnet32TWF
Abs#1586 #ACR22 @Rheumnow https://t.co/PWnkWYdlGk
Aurelie Najm AurelieRheumo ( View Tweet)
"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD
Dr. Rachel Tate uptoTate ( View Tweet)
I see more and more studies on #ArtificialIntelligence using social media posts!
I think this is an extension/future of qualitative studies
40% of posts associated with negative sentiment toward #pregnancy #SLE fear and sadness!
#ACR22 abst#1335 @rheumnow https://t.co/qwk6pYeeXR
Bella Mehta bella_mehta ( View Tweet)
Cycling to 2nd after 1st line TNFi in AxSpA provides
◦ Limited benefits to pts
◦ Few pts showed clinically meaningful improvement in disease severity after 6 months
◦ Less than 25% pts remained on therapy after 2 years
Mease P Abs1499 https://t.co/0Txs82KRbx #ACR22 @RheumNow https://t.co/xJiIWe9yDp
Dr. Antoni Chan synovialjoints ( View Tweet)
Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent patients - better disease activity, reduced GC, less flare, more frequent GC-free remission @RheumNow #ACR22 Abstr#1106 https://t.co/UevgjF8di5 https://t.co/GmXqasNscp
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II RCT. N=78, multi dose phase II RCT. All doses improved DAS28. Dosing interval may be prolonged over time. Awaiting phase 3. Abst#2008 #ACR22 @RheumNow https://t.co/IrzflycKZp
Janet Pope Janetbirdope ( View Tweet)
#abst2132 #acr22 @rheumnow safety of Deucravacitinib Ph2PsA&ph3PSO trial: no Δ from BL in hematology, chemistry, or lipid labs. JAK 1/2/3 Effects on hem, hepatic, CPK, and cholesterol lab parameters not observed over 16 wks of DEUC at doses up to 12 mg QD & in combo w/csDMARDs. https://t.co/bjGEYp4GcJ
Olga Petryna DrPetryna ( View Tweet)
Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of early SSc! @RheumNow #ACR22 Abstr#1536 https://t.co/nKiY2xFxfk https://t.co/W7SDm6QFpQ
Richard Conway RichardPAConway ( View Tweet)
Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Incident aneurysms rare 8%. Older age and secondary cause assoc greater likelyhood improvement, smokers 2 times less likely. @RheumNow #ACR22 Abstr#1576 https://t.co/jS9djx3ZtU https://t.co/OFW2Jk7gGW
Richard Conway RichardPAConway ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Crit #ACR22
Entry: Clinical & +aPL w/in 3 yr
Then: Additive crit
-Don't count other cause
Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology
Lab: +LA, aCL/B2GP IgM/IgG/titer
Total: 3+ clin, 3+ lab
@RheumNow https://t.co/YeKW0orjZC
Eric Dein ericdeinmd ( View Tweet)
⬆️ serum anti-CCP3 Ab, absence IA
👉 StopRA trial - ironically stopped🛑
❌ hydroxychloroquine not superior to PBO in preventing/ delaying IA
👉rate of conversion to RA in CCP3+ve ~35% @ 3yrs
#ACR22 @RheumNow Abst#1604
Patricia Harkins DrTrishHarkins ( View Tweet)
“As long as you are practicing rheumatology, your legal risk is low.” - @greerdonley, law professor, on how rheumatologists should not let fear of legal consequences interfere w/practicing high quality evidenced based medicine for our patients #ReproductiveRheum #ACR22 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)